Add-On Spironolactone for Persistent Proteinuria After Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Patients With Diabetic Kidney Disease: A Retrospective Observational Study
Add-on spironolactone therapy may provide additional renoprotective effects in patients with T2DM and persistent proteinuria despite SGLT2i treatment. Although spironolactone is an older and inexpensive steroidal MRA, it may still represent a clinically meaningful therapeutic option in the contemporary SGLT2i era.
Authors
- Katsunori Jinnouchi
- Noboru Kurinami (ORCID: https://orcid.org/0000-0002-8381-4194)
- Seigo Sugiyama
- Hideaki Jinnouchi
- Akira Yoshida
- Tomoko Suzuki
- Kunio Hieshima
- Fumio Miyamoto
- Keizo Kajiwara
Institutions
- Kumamoto Orthopedic Surgery Hospital (JP)
Publication Details
- Journal
- Cureus
- Published
- 2026-01-28
- DOI
- https://doi.org/10.7759/cureus.102522
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00